Lung Cancer Center, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, Sichuan, People's Republic of China.
World J Surg. 2021 Mar;45(3):897-906. doi: 10.1007/s00268-020-05877-5. Epub 2020 Nov 23.
Whether video-assisted thoracoscopic surgery (VATS) sleeve lobectomy could be an alternative to traditional thoracotomy sleeve lobectomy in treating centrally located non-small cell lung cancer (NSCLC) remains unclear. Therefore, we conducted the first meta-analysis to compare the effects of VATS sleeve lobectomy with thoracotomy sleeve lobectomy.
We systematically searched relevant studies from Pubmed, Embase, and Web of Science on May 12, 2020. Data for analysis included short-term outcomes (blood loss, lymph node dissected, operation time, hospital stay, complications) and long-term outcomes (3-year overall survival (OS) and progression-free survival (PFS) rates). We calculated the weighted mean differences (WMDs) for continuous data and risk ratio (RR) for pooling categorical data.
We finally included 5 retrospective cohort study consisting of 436 patients. VATS sleeve lobectomy yielded significantly less blood loss (WMD = -37.83; 95% confidence intervals (CIs) = [-58.56, -17.11]; P < 0.001) than thoracotomy sleeve lobectomy and comparable total number of dissected lymph node to thoracotomy sleeve lobectomy (WMD = - 0.07; 95%CI = [-1.14, 0.99]; P = 0.89). However, VATS sleeve lobectomy consumed significantly more operation time than thoracotomy sleeve lobectomy (WMD = 49.00; 95%CI = [14.67, 83.34]; P = 0.005). VATS sleeve lobectomy yielded significantly less postoperative hospital stay time than thoracotomy sleeve lobectomy (WMD = -1.68; 95%CI = [-2.98, -0.39]; P = 0.011) and comparable postoperative complication rate to thoracotomy sleeve lobectomy (RR = 0.84; 95%CI = [0.49, 1.44]; P = 0.52). Moreover, VATS sleeve lobectomy yielded comparable 3-year OS (RR = 1.08; 95%CI = [0.95, 1.22]; P = 0.23) and PFS (RR = 1.15; 95%CI = [0.96, 1.37]; P = 0.13) rates to thoracotomy sleeve lobectomy. No significant heterogeneities were observed.
VATS sleeve lobectomy yielded less surgical trauma than thoracotomy sleeve lobectomy and improved postoperative recovery without compromising oncological prognosis. Even though VATS sleeve lobectomy may consume more operation time, it could be recommended as an alternative to thoracotomy sleeve lobectomy for treating centrally located NSCLC in carefully selected cases.
电视辅助胸腔镜手术(VATS)袖状切除术是否可以替代传统的开胸袖状切除术治疗中央型非小细胞肺癌(NSCLC)尚不清楚。因此,我们进行了首次荟萃分析,以比较 VATS 袖状切除术与开胸袖状切除术的效果。
我们于 2020 年 5 月 12 日从 Pubmed、Embase 和 Web of Science 系统地检索了相关研究。分析数据包括短期结果(出血量、淋巴结清扫、手术时间、住院时间、并发症)和长期结果(3 年总生存率(OS)和无进展生存率(PFS)率)。我们计算了连续数据的加权均数差(WMD)和分类数据的风险比(RR)。
我们最终纳入了 5 项回顾性队列研究,共 436 例患者。与开胸袖状切除术相比,VATS 袖状切除术的出血量明显减少(WMD=-37.83;95%置信区间(CI)=-58.56,-17.11;P<0.001),总淋巴结清扫数与开胸袖状切除术相当(WMD=-0.07;95%CI=-1.14,0.99;P=0.89)。然而,VATS 袖状切除术的手术时间明显长于开胸袖状切除术(WMD=49.00;95%CI=14.67,83.34;P=0.005)。VATS 袖状切除术的术后住院时间明显短于开胸袖状切除术(WMD=-1.68;95%CI=-2.98,-0.39;P=0.011),术后并发症发生率与开胸袖状切除术相当(RR=0.84;95%CI=0.49,1.44;P=0.52)。此外,VATS 袖状切除术与开胸袖状切除术的 3 年 OS(RR=1.08;95%CI=0.95,1.22;P=0.23)和 PFS(RR=1.15;95%CI=0.96,1.37;P=0.13)率相当。未观察到显著的异质性。
VATS 袖状切除术比开胸袖状切除术创伤小,术后恢复更快,而不影响肿瘤预后。尽管 VATS 袖状切除术可能需要更长的手术时间,但在仔细选择的情况下,它可以作为治疗中央型 NSCLC 的一种替代方法。